Genenta Science S.p.A. GNTA
At closeNov 3, 2026, 7:35 PM EST
After hours · Nov 3, 7:35 PM ET
- YTD
- -33.89%
- 1 year
- -61.52%
- Market cap
- 47.49M
- EPS (ttm)
- -0.37
- Shares out
- 18.29M
- Forward P/E
- -7.53
- YTD return
- -33.89%
- 1-year return
- -61.52%
- Volume
- 253.56K
- Avg volume
- 77.01K
- Open
- 0.8359
- Previous close
- 0.829
- Day's range
- 0.8189 – 0.99
- 52-week range
- 0.55 – 2.62
- Beta
- 0.74
- Price target
- 21.65 (+2098.3%)
30m +0.1740 (+27.88%)
Key statistics
- Enterprise value
- 74.75M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.45M
- Total cash
- 16.91M
- Total debt
- 21.00K
- Return on equity
- -42.89%
- Short % of float
- 0.01%
- 50-day average
- 5.18
- 200-day average
- 4.10
Analyst view
- Target (low)
- 19.80
- Target (mean)
- 21.65
- Target (high)
- 23.51
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 8, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Jan 5, 2023 | EF Hutton | init | — | Buy |
| Jul 25, 2022 | HC Wainwright & Co. | init | — | Buy |
| Jan 13, 2022 | Maxim Group | init | — | Buy |
About Genenta Science S.p.A.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Italy
- Website
- genenta.com
News
12 Health Care Stocks Moving In Monday's Intraday Session 
Genenta Science Will Do Business As Saentra Forge, With Its ADSs Trading On The Nasdaq Capital Market Under New Ticker Symbol 'SAEN,' Effective November 4 
Genenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial Platform 
Genenta Science Receives Nasdaq Noncompliance Notice, Gets Time Through April 14, 2027 To Regain Compliance 
Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit 
Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm 
Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results 
12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on GNTA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alti Global, Inc. | 1.10% | 200,288 | 980.83K | Sep 29, 2024 |
| Algebris (UK) LTD | 0.25% | 45,000 | 220.37K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 1,862 | 9.12K | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 500 | 2.45K | Sep 29, 2024 |